BIO-TECHNE CORP shareholders Q3 2023

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
INCEPTIONR LLC 9,419$641,1510.36%
MARSHALL WACE, LLP 2,584,615$175,934,7430.36%
Berger Financial Group, Inc 43,784$2,980,3770.34%
LEAVELL INVESTMENT MANAGEMENT, INC. 68,964$4,6940.33%
Alyeska Investment Group, L.P. 710,569$48,368,4320.33%
WESTFIELD CAPITAL MANAGEMENT CO LP 699,662$47,625,9670.32%
Rhenman & Partners Asset Management AB 42,680$2,905,2280.31%
Granite Investment Partners, LLC 109,468$7,451,4870.31%
EAGLE ASSET MANAGEMENT INC 767,844$52,267,1520.31%
Conestoga Capital Advisors, LLC 254,572$17,328,7160.30%
Formidable Asset Management, LLC 19,087$1,299,2230.29%
LWMG, LLC 15,285$1,040,4330.28%
Southeast Asset Advisors Inc. 29,432$2,003,4360.28%
KORNITZER CAPITAL MANAGEMENT INC /KS 192,663$13,114,5700.27%
MACKENZIE FINANCIAL CORP 2,329,033$154,880,6940.26%
CASCADE INVESTMENT GROUP, INC. 4,000$272,2800.26%
Neuberger Berman Group LLC 3,724,068$253,497,3380.23%
NICHOLAS COMPANY, INC. 168,609$11,477,2150.23%
WILKINS INVESTMENT COUNSEL INC 12,450$8470.23%
THRIVENT FINANCIAL FOR LUTHERANS 1,349,853$91,8850.22%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.